Post-traumatic stress disorder (PTSD) is a delayed and persistent mental disorder that occurs when an individual experiences, witnesses, or encounters one or more actual deaths involving himself or others, or is threatened with death, or is severely injured, or whose physical integrity is threatened.The incidence of PTSD has been reported inconsistently, with women more likely to develop PTSD than men.
The global Post-Traumatic Stress Disorder (PTSD) market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Post-Traumatic Stress Disorder (PTSD) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Post-Traumatic Stress Disorder (PTSD) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Post-Traumatic Stress Disorder (PTSD) in Children is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Post-Traumatic Stress Disorder (PTSD) include GlaxoSmithKline (UK), Pfizer (US), Eli Lilly and Company (US), Lundbeck A/S (Denmark), Azevan Pharmaceuticals (US), Marinus Pharmaceuticals, Inc. (US), Tonix Pharmaceuticals Holding Corp. (US), Bionomics (Australia) and Greenstone LLC (US), etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Post-Traumatic Stress Disorder (PTSD), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Post-Traumatic Stress Disorder (PTSD).
Report Scope
The Post-Traumatic Stress Disorder (PTSD) market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Post-Traumatic Stress Disorder (PTSD) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Post-Traumatic Stress Disorder (PTSD) companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
GlaxoSmithKline (UK)
Pfizer (US)
Eli Lilly and Company (US)
Lundbeck A/S (Denmark)
Azevan Pharmaceuticals (US)
Marinus Pharmaceuticals, Inc. (US)
Tonix Pharmaceuticals Holding Corp. (US)
Bionomics (Australia)
Greenstone LLC (US)
Mylan NV (US)
Otsuka Pharmaceutical (Japan)
Prometheon Pharma (USA)
Ligand Pharma (USA)
Valenta Pharm (Russia)
Lycera Corp (US)
Archimedes (UK)
GMP Endotherapeutics (USA)
Nuvo Pharmaceuticals (Canada)
Beijing Wansheng Pharmaceutical
Zhejiang Huahai Pharmaceutical
Zhejiang Jianfeng Pharmaceutical
Segment by Type
Cognitive Therapy
Exposure Therapy
Eye Movement Desensitization And Reprocessing (EMDR)
Antidepressants
Anti-Anxiety Medications
Prazosin
Segment by Application
Children
Adult
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Post-Traumatic Stress Disorder (PTSD) companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Post-Traumatic Stress Disorder (PTSD) Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Cognitive Therapy
1.2.3 Exposure Therapy
1.2.4 Eye Movement Desensitization And Reprocessing (EMDR)
1.2.5 Antidepressants
1.2.6 Anti-Anxiety Medications
1.2.7 Prazosin
1.3 Market by Application
1.3.1 Global Post-Traumatic Stress Disorder (PTSD) Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Children
1.3.3 Adult
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Post-Traumatic Stress Disorder (PTSD) Market Perspective (2019-2030)
2.2 Post-Traumatic Stress Disorder (PTSD) Growth Trends by Region
2.2.1 Global Post-Traumatic Stress Disorder (PTSD) Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Post-Traumatic Stress Disorder (PTSD) Historic Market Size by Region (2019-2024)
2.2.3 Post-Traumatic Stress Disorder (PTSD) Forecasted Market Size by Region (2025-2030)
2.3 Post-Traumatic Stress Disorder (PTSD) Market Dynamics
2.3.1 Post-Traumatic Stress Disorder (PTSD) Industry Trends
2.3.2 Post-Traumatic Stress Disorder (PTSD) Market Drivers
2.3.3 Post-Traumatic Stress Disorder (PTSD) Market Challenges
2.3.4 Post-Traumatic Stress Disorder (PTSD) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Post-Traumatic Stress Disorder (PTSD) Players by Revenue
3.1.1 Global Top Post-Traumatic Stress Disorder (PTSD) Players by Revenue (2019-2024)
3.1.2 Global Post-Traumatic Stress Disorder (PTSD) Revenue Market Share by Players (2019-2024)
3.2 Global Post-Traumatic Stress Disorder (PTSD) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Post-Traumatic Stress Disorder (PTSD) Revenue
3.4 Global Post-Traumatic Stress Disorder (PTSD) Market Concentration Ratio
3.4.1 Global Post-Traumatic Stress Disorder (PTSD) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Post-Traumatic Stress Disorder (PTSD) Revenue in 2023
3.5 Post-Traumatic Stress Disorder (PTSD) Key Players Head office and Area Served
3.6 Key Players Post-Traumatic Stress Disorder (PTSD) Product Solution and Service
3.7 Date of Enter into Post-Traumatic Stress Disorder (PTSD) Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Post-Traumatic Stress Disorder (PTSD) Breakdown Data by Type
4.1 Global Post-Traumatic Stress Disorder (PTSD) Historic Market Size by Type (2019-2024)
4.2 Global Post-Traumatic Stress Disorder (PTSD) Forecasted Market Size by Type (2025-2030)
5 Post-Traumatic Stress Disorder (PTSD) Breakdown Data by Application
5.1 Global Post-Traumatic Stress Disorder (PTSD) Historic Market Size by Application (2019-2024)
5.2 Global Post-Traumatic Stress Disorder (PTSD) Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Post-Traumatic Stress Disorder (PTSD) Market Size (2019-2030)
6.2 North America Post-Traumatic Stress Disorder (PTSD) Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Post-Traumatic Stress Disorder (PTSD) Market Size by Country (2019-2024)
6.4 North America Post-Traumatic Stress Disorder (PTSD) Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Post-Traumatic Stress Disorder (PTSD) Market Size (2019-2030)
7.2 Europe Post-Traumatic Stress Disorder (PTSD) Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Post-Traumatic Stress Disorder (PTSD) Market Size by Country (2019-2024)
7.4 Europe Post-Traumatic Stress Disorder (PTSD) Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Post-Traumatic Stress Disorder (PTSD) Market Size (2019-2030)
8.2 Asia-Pacific Post-Traumatic Stress Disorder (PTSD) Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Post-Traumatic Stress Disorder (PTSD) Market Size by Region (2019-2024)
8.4 Asia-Pacific Post-Traumatic Stress Disorder (PTSD) Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Post-Traumatic Stress Disorder (PTSD) Market Size (2019-2030)
9.2 Latin America Post-Traumatic Stress Disorder (PTSD) Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Post-Traumatic Stress Disorder (PTSD) Market Size by Country (2019-2024)
9.4 Latin America Post-Traumatic Stress Disorder (PTSD) Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Post-Traumatic Stress Disorder (PTSD) Market Size (2019-2030)
10.2 Middle East & Africa Post-Traumatic Stress Disorder (PTSD) Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Post-Traumatic Stress Disorder (PTSD) Market Size by Country (2019-2024)
10.4 Middle East & Africa Post-Traumatic Stress Disorder (PTSD) Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 GlaxoSmithKline (UK)
11.1.1 GlaxoSmithKline (UK) Company Detail
11.1.2 GlaxoSmithKline (UK) Business Overview
11.1.3 GlaxoSmithKline (UK) Post-Traumatic Stress Disorder (PTSD) Introduction
11.1.4 GlaxoSmithKline (UK) Revenue in Post-Traumatic Stress Disorder (PTSD) Business (2019-2024)
11.1.5 GlaxoSmithKline (UK) Recent Development
11.2 Pfizer (US)
11.2.1 Pfizer (US) Company Detail
11.2.2 Pfizer (US) Business Overview
11.2.3 Pfizer (US) Post-Traumatic Stress Disorder (PTSD) Introduction
11.2.4 Pfizer (US) Revenue in Post-Traumatic Stress Disorder (PTSD) Business (2019-2024)
11.2.5 Pfizer (US) Recent Development
11.3 Eli Lilly and Company (US)
11.3.1 Eli Lilly and Company (US) Company Detail
11.3.2 Eli Lilly and Company (US) Business Overview
11.3.3 Eli Lilly and Company (US) Post-Traumatic Stress Disorder (PTSD) Introduction
11.3.4 Eli Lilly and Company (US) Revenue in Post-Traumatic Stress Disorder (PTSD) Business (2019-2024)
11.3.5 Eli Lilly and Company (US) Recent Development
11.4 Lundbeck A/S (Denmark)
11.4.1 Lundbeck A/S (Denmark) Company Detail
11.4.2 Lundbeck A/S (Denmark) Business Overview
11.4.3 Lundbeck A/S (Denmark) Post-Traumatic Stress Disorder (PTSD) Introduction
11.4.4 Lundbeck A/S (Denmark) Revenue in Post-Traumatic Stress Disorder (PTSD) Business (2019-2024)
11.4.5 Lundbeck A/S (Denmark) Recent Development
11.5 Azevan Pharmaceuticals (US)
11.5.1 Azevan Pharmaceuticals (US) Company Detail
11.5.2 Azevan Pharmaceuticals (US) Business Overview
11.5.3 Azevan Pharmaceuticals (US) Post-Traumatic Stress Disorder (PTSD) Introduction
11.5.4 Azevan Pharmaceuticals (US) Revenue in Post-Traumatic Stress Disorder (PTSD) Business (2019-2024)
11.5.5 Azevan Pharmaceuticals (US) Recent Development
11.6 Marinus Pharmaceuticals, Inc. (US)
11.6.1 Marinus Pharmaceuticals, Inc. (US) Company Detail
11.6.2 Marinus Pharmaceuticals, Inc. (US) Business Overview
11.6.3 Marinus Pharmaceuticals, Inc. (US) Post-Traumatic Stress Disorder (PTSD) Introduction
11.6.4 Marinus Pharmaceuticals, Inc. (US) Revenue in Post-Traumatic Stress Disorder (PTSD) Business (2019-2024)
11.6.5 Marinus Pharmaceuticals, Inc. (US) Recent Development
11.7 Tonix Pharmaceuticals Holding Corp. (US)
11.7.1 Tonix Pharmaceuticals Holding Corp. (US) Company Detail
11.7.2 Tonix Pharmaceuticals Holding Corp. (US) Business Overview
11.7.3 Tonix Pharmaceuticals Holding Corp. (US) Post-Traumatic Stress Disorder (PTSD) Introduction
11.7.4 Tonix Pharmaceuticals Holding Corp. (US) Revenue in Post-Traumatic Stress Disorder (PTSD) Business (2019-2024)
11.7.5 Tonix Pharmaceuticals Holding Corp. (US) Recent Development
11.8 Bionomics (Australia)
11.8.1 Bionomics (Australia) Company Detail
11.8.2 Bionomics (Australia) Business Overview
11.8.3 Bionomics (Australia) Post-Traumatic Stress Disorder (PTSD) Introduction
11.8.4 Bionomics (Australia) Revenue in Post-Traumatic Stress Disorder (PTSD) Business (2019-2024)
11.8.5 Bionomics (Australia) Recent Development
11.9 Greenstone LLC (US)
11.9.1 Greenstone LLC (US) Company Detail
11.9.2 Greenstone LLC (US) Business Overview
11.9.3 Greenstone LLC (US) Post-Traumatic Stress Disorder (PTSD) Introduction
11.9.4 Greenstone LLC (US) Revenue in Post-Traumatic Stress Disorder (PTSD) Business (2019-2024)
11.9.5 Greenstone LLC (US) Recent Development
11.10 Mylan NV (US)
11.10.1 Mylan NV (US) Company Detail
11.10.2 Mylan NV (US) Business Overview
11.10.3 Mylan NV (US) Post-Traumatic Stress Disorder (PTSD) Introduction
11.10.4 Mylan NV (US) Revenue in Post-Traumatic Stress Disorder (PTSD) Business (2019-2024)
11.10.5 Mylan NV (US) Recent Development
11.11 Otsuka Pharmaceutical (Japan)
11.11.1 Otsuka Pharmaceutical (Japan) Company Detail
11.11.2 Otsuka Pharmaceutical (Japan) Business Overview
11.11.3 Otsuka Pharmaceutical (Japan) Post-Traumatic Stress Disorder (PTSD) Introduction
11.11.4 Otsuka Pharmaceutical (Japan) Revenue in Post-Traumatic Stress Disorder (PTSD) Business (2019-2024)
11.11.5 Otsuka Pharmaceutical (Japan) Recent Development
11.12 Prometheon Pharma (USA)
11.12.1 Prometheon Pharma (USA) Company Detail
11.12.2 Prometheon Pharma (USA) Business Overview
11.12.3 Prometheon Pharma (USA) Post-Traumatic Stress Disorder (PTSD) Introduction
11.12.4 Prometheon Pharma (USA) Revenue in Post-Traumatic Stress Disorder (PTSD) Business (2019-2024)
11.12.5 Prometheon Pharma (USA) Recent Development
11.13 Ligand Pharma (USA)
11.13.1 Ligand Pharma (USA) Company Detail
11.13.2 Ligand Pharma (USA) Business Overview
11.13.3 Ligand Pharma (USA) Post-Traumatic Stress Disorder (PTSD) Introduction
11.13.4 Ligand Pharma (USA) Revenue in Post-Traumatic Stress Disorder (PTSD) Business (2019-2024)
11.13.5 Ligand Pharma (USA) Recent Development
11.14 Valenta Pharm (Russia)
11.14.1 Valenta Pharm (Russia) Company Detail
11.14.2 Valenta Pharm (Russia) Business Overview
11.14.3 Valenta Pharm (Russia) Post-Traumatic Stress Disorder (PTSD) Introduction
11.14.4 Valenta Pharm (Russia) Revenue in Post-Traumatic Stress Disorder (PTSD) Business (2019-2024)
11.14.5 Valenta Pharm (Russia) Recent Development
11.15 Lycera Corp (US)
11.15.1 Lycera Corp (US) Company Detail
11.15.2 Lycera Corp (US) Business Overview
11.15.3 Lycera Corp (US) Post-Traumatic Stress Disorder (PTSD) Introduction
11.15.4 Lycera Corp (US) Revenue in Post-Traumatic Stress Disorder (PTSD) Business (2019-2024)
11.15.5 Lycera Corp (US) Recent Development
11.16 Archimedes (UK)
11.16.1 Archimedes (UK) Company Detail
11.16.2 Archimedes (UK) Business Overview
11.16.3 Archimedes (UK) Post-Traumatic Stress Disorder (PTSD) Introduction
11.16.4 Archimedes (UK) Revenue in Post-Traumatic Stress Disorder (PTSD) Business (2019-2024)
11.16.5 Archimedes (UK) Recent Development
11.17 GMP Endotherapeutics (USA)
11.17.1 GMP Endotherapeutics (USA) Company Detail
11.17.2 GMP Endotherapeutics (USA) Business Overview
11.17.3 GMP Endotherapeutics (USA) Post-Traumatic Stress Disorder (PTSD) Introduction
11.17.4 GMP Endotherapeutics (USA) Revenue in Post-Traumatic Stress Disorder (PTSD) Business (2019-2024)
11.17.5 GMP Endotherapeutics (USA) Recent Development
11.18 Nuvo Pharmaceuticals (Canada)
11.18.1 Nuvo Pharmaceuticals (Canada) Company Detail
11.18.2 Nuvo Pharmaceuticals (Canada) Business Overview
11.18.3 Nuvo Pharmaceuticals (Canada) Post-Traumatic Stress Disorder (PTSD) Introduction
11.18.4 Nuvo Pharmaceuticals (Canada) Revenue in Post-Traumatic Stress Disorder (PTSD) Business (2019-2024)
11.18.5 Nuvo Pharmaceuticals (Canada) Recent Development
11.19 Beijing Wansheng Pharmaceutical
11.19.1 Beijing Wansheng Pharmaceutical Company Detail
11.19.2 Beijing Wansheng Pharmaceutical Business Overview
11.19.3 Beijing Wansheng Pharmaceutical Post-Traumatic Stress Disorder (PTSD) Introduction
11.19.4 Beijing Wansheng Pharmaceutical Revenue in Post-Traumatic Stress Disorder (PTSD) Business (2019-2024)
11.19.5 Beijing Wansheng Pharmaceutical Recent Development
11.20 Zhejiang Huahai Pharmaceutical
11.20.1 Zhejiang Huahai Pharmaceutical Company Detail
11.20.2 Zhejiang Huahai Pharmaceutical Business Overview
11.20.3 Zhejiang Huahai Pharmaceutical Post-Traumatic Stress Disorder (PTSD) Introduction
11.20.4 Zhejiang Huahai Pharmaceutical Revenue in Post-Traumatic Stress Disorder (PTSD) Business (2019-2024)
11.20.5 Zhejiang Huahai Pharmaceutical Recent Development
11.21 Zhejiang Jianfeng Pharmaceutical
11.21.1 Zhejiang Jianfeng Pharmaceutical Company Detail
11.21.2 Zhejiang Jianfeng Pharmaceutical Business Overview
11.21.3 Zhejiang Jianfeng Pharmaceutical Post-Traumatic Stress Disorder (PTSD) Introduction
11.21.4 Zhejiang Jianfeng Pharmaceutical Revenue in Post-Traumatic Stress Disorder (PTSD) Business (2019-2024)
11.21.5 Zhejiang Jianfeng Pharmaceutical Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
GlaxoSmithKline (UK)
Pfizer (US)
Eli Lilly and Company (US)
Lundbeck A/S (Denmark)
Azevan Pharmaceuticals (US)
Marinus Pharmaceuticals, Inc. (US)
Tonix Pharmaceuticals Holding Corp. (US)
Bionomics (Australia)
Greenstone LLC (US)
Mylan NV (US)
Otsuka Pharmaceutical (Japan)
Prometheon Pharma (USA)
Ligand Pharma (USA)
Valenta Pharm (Russia)
Lycera Corp (US)
Archimedes (UK)
GMP Endotherapeutics (USA)
Nuvo Pharmaceuticals (Canada)
Beijing Wansheng Pharmaceutical
Zhejiang Huahai Pharmaceutical
Zhejiang Jianfeng Pharmaceutical
听
听
*If Applicable.
